Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
Background: Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated i...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
BioMed Central
2018
|
| Subjects: |
| _version_ | 1825721495204134912 |
|---|---|
| author | Vasaikar, Suhas Tsipras, Giorgos Landázuri, Natalia Costa, Helena Wilhelmi, Vanessa Scicluna, Patrick Cui, Huanhuan L. Mohammad, Abdul Aleem Davoudi, Belghis Shang, Mingmei Ananthaseshan, Sharan Strååt, Klas Stragliotto, Giuseppe Rahbar, Afsar Wong, Kum Thong Tegner, Jesper Yaiw, Koon Chu Söderberg-Naucler, Cecilia |
| author_facet | Vasaikar, Suhas Tsipras, Giorgos Landázuri, Natalia Costa, Helena Wilhelmi, Vanessa Scicluna, Patrick Cui, Huanhuan L. Mohammad, Abdul Aleem Davoudi, Belghis Shang, Mingmei Ananthaseshan, Sharan Strååt, Klas Stragliotto, Giuseppe Rahbar, Afsar Wong, Kum Thong Tegner, Jesper Yaiw, Koon Chu Söderberg-Naucler, Cecilia |
| author_sort | Vasaikar, Suhas |
| collection | UM |
| description | Background: Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated in gliomas, we aimed to test whether ETBR is a useful prognostic marker in GBM and examine if the clinically available endothelin receptor antagonists (ERA) could be useful in the disease treatment. Methods: Data from The Cancer Genome Atlas and the Gene Expression Omnibus database were analyzed to assess ETBR expression. For survival analysis, glioblastoma samples from 25 Swedish patients were immunostained for ETBR, and the findings were correlated with clinical history. The druggability of ETBR was assessed by protein-protein interaction network analysis. ERAs were analyzed for toxicity in in vitro assays with GBM and breast cancer cells. Results: By bioinformatics analysis, ETBR was found to be upregulated in glioblastoma patients, and its expression levels were correlated with reduced survival. ETBR interacts with key proteins involved in cancer pathogenesis, suggesting it as a druggable target. In vitro viability assays showed that ERAs may hold promise to treat glioblastoma and breast cancer. Conclusions: ETBR is overexpressed in glioblastoma and other cancers and may be a prognostic marker in glioblastoma. ERAs may be useful for treating cancer patients. |
| first_indexed | 2024-03-06T05:51:11Z |
| format | Article |
| id | um.eprints-20429 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:51:11Z |
| publishDate | 2018 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | um.eprints-204292019-02-21T04:47:54Z http://eprints.um.edu.my/20429/ Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? Vasaikar, Suhas Tsipras, Giorgos Landázuri, Natalia Costa, Helena Wilhelmi, Vanessa Scicluna, Patrick Cui, Huanhuan L. Mohammad, Abdul Aleem Davoudi, Belghis Shang, Mingmei Ananthaseshan, Sharan Strååt, Klas Stragliotto, Giuseppe Rahbar, Afsar Wong, Kum Thong Tegner, Jesper Yaiw, Koon Chu Söderberg-Naucler, Cecilia R Medicine Background: Glioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated in gliomas, we aimed to test whether ETBR is a useful prognostic marker in GBM and examine if the clinically available endothelin receptor antagonists (ERA) could be useful in the disease treatment. Methods: Data from The Cancer Genome Atlas and the Gene Expression Omnibus database were analyzed to assess ETBR expression. For survival analysis, glioblastoma samples from 25 Swedish patients were immunostained for ETBR, and the findings were correlated with clinical history. The druggability of ETBR was assessed by protein-protein interaction network analysis. ERAs were analyzed for toxicity in in vitro assays with GBM and breast cancer cells. Results: By bioinformatics analysis, ETBR was found to be upregulated in glioblastoma patients, and its expression levels were correlated with reduced survival. ETBR interacts with key proteins involved in cancer pathogenesis, suggesting it as a druggable target. In vitro viability assays showed that ERAs may hold promise to treat glioblastoma and breast cancer. Conclusions: ETBR is overexpressed in glioblastoma and other cancers and may be a prognostic marker in glioblastoma. ERAs may be useful for treating cancer patients. BioMed Central 2018 Article PeerReviewed Vasaikar, Suhas and Tsipras, Giorgos and Landázuri, Natalia and Costa, Helena and Wilhelmi, Vanessa and Scicluna, Patrick and Cui, Huanhuan L. and Mohammad, Abdul Aleem and Davoudi, Belghis and Shang, Mingmei and Ananthaseshan, Sharan and Strååt, Klas and Stragliotto, Giuseppe and Rahbar, Afsar and Wong, Kum Thong and Tegner, Jesper and Yaiw, Koon Chu and Söderberg-Naucler, Cecilia (2018) Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? BMC Cancer, 18 (1). p. 154. ISSN 1471-2407, DOI https://doi.org/10.1186/s12885-018-4012-7 <https://doi.org/10.1186/s12885-018-4012-7>. https://doi.org/10.1186/s12885-018-4012-7 doi:10.1186/s12885-018-4012-7 |
| spellingShingle | R Medicine Vasaikar, Suhas Tsipras, Giorgos Landázuri, Natalia Costa, Helena Wilhelmi, Vanessa Scicluna, Patrick Cui, Huanhuan L. Mohammad, Abdul Aleem Davoudi, Belghis Shang, Mingmei Ananthaseshan, Sharan Strååt, Klas Stragliotto, Giuseppe Rahbar, Afsar Wong, Kum Thong Tegner, Jesper Yaiw, Koon Chu Söderberg-Naucler, Cecilia Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title | Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title_full | Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title_fullStr | Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title_full_unstemmed | Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title_short | Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? |
| title_sort | overexpression of endothelin b receptor in glioblastoma a prognostic marker and therapeutic target |
| topic | R Medicine |
| work_keys_str_mv | AT vasaikarsuhas overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT tsiprasgiorgos overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT landazurinatalia overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT costahelena overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT wilhelmivanessa overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT sciclunapatrick overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT cuihuanhuanl overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT mohammadabdulaleem overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT davoudibelghis overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT shangmingmei overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT ananthaseshansharan overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT straatklas overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT stragliottogiuseppe overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT rahbarafsar overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT wongkumthong overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT tegnerjesper overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT yaiwkoonchu overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget AT soderbergnauclercecilia overexpressionofendothelinbreceptoringlioblastomaaprognosticmarkerandtherapeutictarget |